Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01088763 · ClinicalTrials.gov registry record · Phase 1
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
NCT01088763: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01088763 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01088763, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
Study Summary
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG dexamethasone
- OTHER pharmacological study
- OTHER diagnostic laboratory biomarker analysis
- DRUG gamma-secretase/Notch signalling pathway inhibitor RO4929097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01088763
The ClinicalTrials.gov registry entry for NCT01088763 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT01088763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01088763 about?
NCT01088763 is a clinical study titled "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia". This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop th...
What is the current status of trial NCT01088763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2010-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01088763?
The interventions under investigation include: dexamethasone (DRUG), pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), gamma-secretase/Notch signalling pathway inhibitor RO4929097 (DRUG).
Who is sponsoring clinical trial NCT01088763?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.